Hypertension and sensorineural hearing loss: relevance of the problem and the specifics of treatment (focus on Olmesartan)

Abstract

Information about retraction of an articleAnalysis conducted by the members of the editorial board has revealed the presence of direct borrowing without reference to the source of citations in the following articles:The article by Evdokimova A.G., Yunko S.A., Gunchikov M.V. Arterial hypertension and sensorineural hearing loss: immediacy of the problem and treatment characteristics (focus on olmesartan) and the article by Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I The role of sartans in the treatment of hypertension: focus on olmesartan // Consilium Medicum – 2012 - No. 10 – p. 10-15.Based on the decision of the Editorial Board of the journal Medical Council dated January 17, 2020, the following article has been retracted:Evdokimova A.G., Yunko S.A., Gunchikov M.V. Hypertension and sensorineural hearing loss: relevance of the problem and the specifics of treatment (focus on Olmesartan)// Meditsinskiy sovet = Medical Council – 2015 - No.2 – p. 46-51.Arterial hypertension (AH) is the most relevant risk factor for cardiovascular complications requiring adequate organ-protective treatment. In 17--19% of cases hypertension is combined with sensorineural hearing loss (SNHL). The article tells about antihypertensive therapy in patients with SNHL and mechanisms of its pathogenesis. A clinical case of long-term successful administration of olmesartan in a patient with AH and SNHL is described.

Keywords

• артериальная гипертония
• нейросенсорная тугоухость
• олмесартан
• hypertension
• sensorineural hearing loss
• olmesartan